2022
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial
Strober B, Stein Gold L, Bissonnette R, Armstrong A, Kircik L, Tyring S, Piscitelli S, Brown P, Rubenstein D, Tallman A, Lebwohl M. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. Journal Of The American Academy Of Dermatology 2022, 87: 800-806. PMID: 35772599, DOI: 10.1016/j.jaad.2022.06.1171.Peer-Reviewed Original ResearchConceptsOpen-label treatmentRemittive effectsPlaque psoriasisUpper respiratory tract infectionPhysician Global Assessment scoreComplete disease clearanceOne-year safetyFrequent adverse eventsSevere plaque psoriasisNew safety signalsPhase 3 trialRespiratory tract infectionsDurability of responseForms of psoriasisGlobal assessment scoreLong-term safetyEligible patientsTapinarof creamDisease clearanceAdverse eventsTract infectionsMean durationSafety signalsContact dermatitisCream 1
2012
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp K, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. Journal Of Drugs In Dermatology 2012, 11: 1210-7. PMID: 23134986.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticBody Mass IndexBody Surface AreaCardiovascular DiseasesData Interpretation, StatisticalFemaleHumansImmunologic FactorsInfliximabMaleMiddle AgedObesityPhototherapyProduct Surveillance, PostmarketingProspective StudiesPsoriasisRegistriesUstekinumabConceptsDisease-based registryBiologic agentsObservational studyMajor adverse cardiovascular eventsConventional systemic treatmentsGeneral psoriasis populationPsoriasis Longitudinal AssessmentAdverse cardiovascular eventsOverweight/obeseLong-term observational studyBody surface areaPsoriasis populationCardiovascular eventsCause mortalityAdverse eventsPsoriatic arthritisRegistry studySystemic agentsSystemic therapySystemic treatmentMedication historyDisease characteristicsSerious infectionsMean durationEfficacy data